30th Oct 2015 08:30
30 October 2015
Clinigen Group plc
Completion of Acquisition of Link
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global specialty pharmaceuticals business, has today completed the acquisition of Link Healthcare Private Limited ("Link") which was announced on 22 September 2015 (the "Acquisition").
As a result of the completion of the Acquisition ("Completion"), 3,102,558 new ordinary shares in the Group have been allotted, credited as fully paid, to the vendors of Link.
Accordingly, the Group now has in issue 114,553,730 ordinary shares of 0.1p each, with voting rights. Clinigen does not hold any shares in treasury. This figure of 114,553,730 ordinary shares may be used by shareholders in Clinigen to determine if they are required to notify their interest in, or a change in their interest in, Clinigen under the Financial Conduct Authority's Disclosure and Transparency Rules.
Peter George, Chief Executive Officer of Clinigen, said:
"The completion of this strategic acquisition strengthens our international distribution network across the AAA region - Asia, Africa and Australasia. We welcome Link to the Group and look forward to being even better placed to directly supply much needed, but not always licensed, medicines into the growing 'pharmerging' markets.
"Together, our combined entity further supports our underlying philosophy of getting the right drug to the right patient at the right time regardless of the location anywhere in the world."
Upon Completion, John Bacon, Group Chairman and Founder of Link, was appointed to the Clinigen Board as a Non-Executive Director. Please see separate announcement.
-Ends-
Contact Details
Clinigen Group plc |
Tel: +44 (0) 1283 495010 |
Peter George, Group Chief Executive Officer Shaun Chilton, Group Deputy Chief Executive Officer Martin Abell, Group Chief Financial Officer | |
Numis Securities Limited |
Tel: +44 (0) 20 7260 1000 |
Michael Meade/Freddie Barnfield (Nominated Adviser) James Black/Tom Ballard (Corporate Broking) | |
Peel Hunt LLP |
Tel: +44 (0) 20 7418 8900 |
James Steel/Jock Maxwell Macdonald | |
Instinctif Partners |
Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow | Email: [email protected] |
Notes to Editors
About Clinigen Group
Clinigen Group is a global pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time. The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; Clinigen CTS manages the supply of commercial medicines for clinical trials; Idis Managed Access runs early access programs for Clinigen's own and other companies' portfolios; Idis Global Access works directly with healthcare providers to enable ethical compliant access to unlicensed medicines and Clinigen SP acquires and markets our own portfolio of hospital only niche medicines.
Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need.
For more information, please visit www.clinigengroup.com.
Related Shares:
CLIN.L